Primary ovarian insufficiency

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients

Retrieved on: 
Monday, December 11, 2023
Urine, Reproduction, Skeleton, Headache, PSA, Kidney, Erythroderma, Patient, Pharmacy, Birth, Nephrotic syndrome, MBA, Cancer, Miscarriage, Safety, Incidence, VTE, Bevacizumab, Corneal opacity, Wound healing, VEGFR2, Gastrointestinal perforation, Hemoptysis, Female, Fetus, CHF, Celltrion, Pharming, Necrotizing fasciitis, Heart failure, Fistula, Risk, Tracheoesophageal fistula, Bleeding, Organogenesis, Partnership, Rhinitis, Hypertension, Primary ovarian insufficiency, Back pain, Pregnancy, Glioblastoma, PRES, Nosebleed, Skull, FDA, ATE, VEGF, MBM, Hypertensive encephalopathy, Toxicity, Nursing, Pharmaceutical industry, Birth control, Dietary supplement, Proteinuria

Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.

Key Points: 
  • Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.
  • Gastrointestinal Perforations and Fistula: Discontinue for gastrointestinal perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ.
  • Surgery and Wound Healing Complications: In patients who experience wound healing complications during VEGZELMA treatment, withhold VEGZELMA until adequate wound healing.
  • Do not administer VEGZELMA for at least 28 days following a major surgery, and until adequate wound healing.

Myovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine Fibroids

Retrieved on: 
Wednesday, May 17, 2023
Wearables, Mobile Technology, Technology, Women, Health Technology, Software, Consumer, Health, Data Management, Science, Other Science, Endometriosis, Pelvic inflammatory disease, Life, Education, Workplace, Absenteeism, Dysmenorrhea, Statistics, Innovation, Multimedia, Cycle, Interface (computing), Meigs's syndrome, Roivant Sciences, Uterine fibroid, Fibroid, Menstrual cycle, Diagnosis, Entrepreneurship, Ageing, Uterine cancer, Primary ovarian insufficiency, Ovarian cancer, Environment, Female, Nursing, Management, Medical device, Medical imaging, Birth control, Evidence-based policy

Today, as part of National Women’s Health Week, Evidation and Myovant Sciences Ltd. (“Myovant”), a wholly owned subsidiary of Sumitovant Biopharma Ltd. (“Sumitovant”) announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.

Key Points: 
  • Today, as part of National Women’s Health Week, Evidation and Myovant Sciences Ltd. (“Myovant”), a wholly owned subsidiary of Sumitovant Biopharma Ltd. (“Sumitovant”) announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.
  • View the full release here: https://www.businesswire.com/news/home/20230517005194/en/
    “At Myovant, we know that stigma can often keep people quiet about periods, leading to delayed care and increased discomfort.
  • It also contributes to the lack of awareness about how conditions such as endometriosis and uterine fibroids can increase absenteeism and impact performance at work and school,” said Kalahn Taylor-Clark, vice president and head of Strategic Partnerships and Innovation at Myovant Sciences.
  • The survey covered four areas, including demographics, menstrual history and health, experiences at work or school, and experiences with medical providers.

Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Recipients Announced

Retrieved on: 
Tuesday, April 18, 2023
Research, Philanthropy, Other Health, Biotechnology, Alternative Medicine, General Health, Health, Foundation, Science, Other Science, University of Texas Southwestern Medical Center, Exercise, American Federation for Aging Research, Workforce, Neuron, BAT, Partnership, University of Pittsburgh, University, University of Oklahoma Health Sciences Center, Wake Forest School of Medicine, Therapy, Associate professor, Monash University, Boston University Chobanian & Avedisian School of Medicine, Ageing, University of New South Wales, Brain, Primary ovarian insufficiency, Intravital microscopy, Research fellow, Doctor of Philosophy, American Federation of Aviculture, Assistant, Boston University School of Public Health, EDM, Notifiable disease, AFAR, Assistant professor, National Center for Advancing Translational Sciences, Lipid metabolism, Senescence, Biology, Wound healing, Pharmaceutical industry, Management, Nursing

Hevolution Foundation and the American Federation for Aging Research ( AFAR ) are pleased to announce the inaugural Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research recipients.

Key Points: 
  • Hevolution Foundation and the American Federation for Aging Research ( AFAR ) are pleased to announce the inaugural Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research recipients.
  • Eighteen three-year awards of $375,000 each, for a total of $6.75 Million, have been granted to support research projects in the basic biology of aging or geroscience, a research paradigm based on addressing the biology of aging and age-related disease to promote healthy aging.
  • “Some of the biggest breakthroughs in aging research today were funded first through AFAR’s grants for promising early career researchers.
  • The Hevolution/AFAR New Investigator Awards in Aging Biology and Geroscience Research will significantly boost support for junior faculty worldwide,” noted Stephanie Lederman, EdM, Executive Director, AFAR.

Global In Vitro Fertilization (IVF) Market Report 2023: Increasing Median Age of First-Time Mothers Drives Growth

Retrieved on: 
Thursday, February 23, 2023
Ovulation, Infertility, Biomedical engineering, Female, Knowledge, Clinical, Brigham and Women's Hospital, IVF, Patient, The Cooper Companies, Primary ovarian insufficiency, Artificial intelligence, ALF, Physician, Maintenance, Laboratory, Fertilisation, Tubing (recreation), Research, Massachusetts General Hospital, Oocyte, ART, Fertility clinic, AI, Child, Growth, Generate, Uterine fibroid, Incubator, Male, HSA, Woman, Single, Hospital, Birth control, Medical device

DUBLIN, Feb. 23, 2023 /PRNewswire/ -- The "Global In Vitro Fertilization (IVF) Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 23, 2023 /PRNewswire/ -- The "Global In Vitro Fertilization (IVF) Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Growing public understanding and acceptance of infertility treatment will encourage the use of in vitro fertilization (IVF) methods, which will accelerate the development of the in vitro fertilization (IVF) market.
  • However, the main factor limiting the potential market for in vitro fertilization (IVF) is the cost of the treatments, which is well-known around the world.
  • The effective use of contraceptives has also significantly influenced the median age of first-time mothers, and this is anticipated to significantly fuel the expansion of the in vitro fertilization (IVF) market.

New research from Shady Grove Fertility (SGF) can help provide an optimal age for egg donors and those pursuing elective egg freezing

Retrieved on: 
Wednesday, October 26, 2022
Physician, Insurance, Congress, SGF, Directorate of Research and Civil Affairs, Gynaecology, Sterility, K Street, Family, Parent, Patient, Primary ovarian insufficiency, Partnership, Dream, Health, Egg, IVF, Fertility, SoHo, Manhattan, ASRM, Ovarian reserve, Pregnancy, Pregnancy rate, Medical device, Hospital, Infertility, Obstetrics, MD, Research

ROCKVILLE, Md., Oct. 26, 2022 /PRNewswire-PRWeb/ -- New research from Shady Grove Fertility (SGF) conducted with Donor Egg Bank USA offers reassurance for intended parents growing their family with the use of an egg donor and can offer guidance to patients pursuing elective egg freezing.

Key Points: 
  • ROCKVILLE, Md., Oct. 26, 2022 /PRNewswire-PRWeb/ -- New research from Shady Grove Fertility (SGF) conducted with Donor Egg Bank USA offers reassurance for intended parents growing their family with the use of an egg donor and can offer guidance to patients pursuing elective egg freezing.
  • "At SGF, we pride ourselves in providing evidence-based fertility care; therefore, our research team conducted a study to help guide intended parents who are growing their family through egg donation."
  • The SGF research team looked at egg donor recipient cycles at Donor Egg Bank USA between 2013 and 2021.
  • SGF is among the founding partner practices of US Fertility , the largest physician-led partnership of top-tier fertility practices in the U.S.

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

Retrieved on: 
Thursday, October 20, 2022
News, Primary ovarian insufficiency, Nasdaq Market Makers Antitrust Litigation, Time, Cell bank, U.S. Securities and Exchange Commission, Immortalised cell line, Investigational New Drug, Drug, Drug Master File, Commission, NASDAQ, Biotechnology, Security (finance), Multimedia, Urology, Neurology, CEO, Endocrinology, Immunotherapy, Forward-looking statement, Low back pain, Elective surgery, FDA, View, Pharmaceutical industry, 3D printing

PHOENIX, Oct. 20, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, announced today that through predominantly internal and collaborative development, it has produced an allogenic Cell Line called AlloStem, which includes a Master Cell Bank and a Drug Master File which shall be submitted for FDA registration.

Key Points: 
  • PHOENIX, Oct. 20, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, announced today that through predominantly internal and collaborative development, it has produced an allogenic Cell Line called AlloStem, which includes a Master Cell Bank and a Drug Master File which shall be submitted for FDA registration.
  • Creative Medical Technology Holdings, Inc. is a biotechnology company specializing in regenerative medicine/stem cell technology in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics and is traded on NASDAQ under the ticker symbol CELZ.
  • See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov .
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/creative-medical-technology-hol...
    SOURCE Creative Medical Technology Holdings, Inc.

FDA Approves First IND of its Kind for Allogenic Exosomal Treatment of Female Reproductive Disorder - Primary Ovarian Insufficiency

Retrieved on: 
Tuesday, October 18, 2022
Disease, Primary ovarian insufficiency, IND, Woman, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, POI, Patient, Depression, Research, Knowledge, Food, Cancer, PCOS, Pure, Clinical trial, Polycystic ovary syndrome, Infertility, Anxiety, FDA, Pharmaceutical industry

The approved human clinical trial is based on non-clinical studies in cell culture and animal models utilizing EV-Pure, which indicated a strong promise for the reversal of POI.

Key Points: 
  • The approved human clinical trial is based on non-clinical studies in cell culture and animal models utilizing EV-Pure, which indicated a strong promise for the reversal of POI.
  • Primary Ovarian Insufficiency leads to infertility in about 1 in 100 women under 40 years of age, in general, and as high as 82% of cancer survivors.
  • Several experimental treatments have been tried for Primary Ovarian Insufficiency without success, making no current treatment available on the market.
  • An off-the-shelf treatment such as this, could give women an economical solution for this devastating disease process who are unable to conceive."

Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States

Retrieved on: 
Monday, October 3, 2022
Oncology, Health, Biometrics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Gastrointestinal perforation, Nephrotic syndrome, Cancer, Carboplatin, Primary ovarian insufficiency, Time, SVP, Ownership, Wound healing, Research, Private Securities Litigation Reform Act, Common stock, Disulfiram-like drug, Kidney, Weather, Nosebleed, Back pain, FDA, Buy, Fistula, COVID-19, Forward-looking statement, Paclitaxel, Headache, Annual report, Growth, Medication, Degenerative disease, Metastasis, U.S. Securities and Exchange Commission, Investment, Generic, Federation, Bleeding, NYSE, Large-cell lung carcinoma, Security (finance), Bevacizumab, Amneal Pharmaceuticals, Patient, Cisplatin, Proteinuria, Heart, Hypertension, Alfa, Central nervous system, Rhinitis, Intellectual property, Risk, Therapy, Company, Hypertensive encephalopathy, Fine chemical, Generic drug, Pharmaceutical industry, Platinum, Risk management, Topotecan

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the commercial launch of ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the commercial launch of ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin.
  • The launch of ALYMSYS provides additional access and choice to affordable oncology therapeutics for providers and patients.
  • Amneal has officially entered the U.S. biosimilar market.
  • We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States.

Fertility Services Global Market 2022: Adopting IoT Enabled Solutions in Fertility to Carry Out Operations and Connecting to More Than One Location Present Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 8, 2022
General Health, Women, Consumer, Health, Baby, Maternity, Birth, Technology, Fertility clinic, Application, Solution, Insurance, Coronavirus, PCOS, Male, Procedure, IVF, Adoption, Primary ovarian insufficiency, Prevalence, CAGR, Patient, Infertility, Growth, Polycystic ovary syndrome, Observation, Polycystic disease, Pregnancy, Agriculture, Pet, Birth control, Fertility

The "Fertility Services Global Market Opportunities And Strategies To 2030, By Procedure, Service, Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fertility Services Global Market Opportunities And Strategies To 2030, By Procedure, Service, Application" report has been added to ResearchAndMarkets.com's offering.
  • The global fertility services market is expected to grow from $24,466.2 million in 2015 to $37,773.7 million in 2020 at a compound annual growth rate (CAGR) of 9.1%.
  • The global fertility services market is expected to reach $161,846.9 million in 2030, at a CAGR of 15.7%.
  • Western Europe was the largest region in the global fertility services market, accounting for 30.8% of the total in 2020.

Global Gynecology Partnering Deal Trends, Players and Financials Report/Directory 2010-2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
General Health, Other Professional Services, Professional Services, Health, Pelvic inflammatory disease, Chapter Six, Menopause, Technology, Research, HPV, Premenstrual syndrome, Finance, Players, Vaginitis, Chapter One, SEC, Orientation, CIN, Chapter Two, Chapter Three, Chapter Five, Directory, Cervical intraepithelial neoplasia, Hyperlink, Chapter Four, Adenomyosis, Primary ovarian insufficiency, Polycystic ovary syndrome, Polycystic disease, Review, Contract, Video game, Birth control, Risk management, Sales, Endometriosis, Prolapse, Infertility, Dysmenorrhea, Amenorrhea, Gynaecology

The "Global Gynecology Partnering 2010-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gynecology Partnering 2010-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Gynecology Partnering 2010-2022 report provides comprehensive access to available deals and contract documents for over 490 gynecology deals.
  • The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals.
  • Global Gynecology Partnering 2010 to 2022 includes:
    In Global Gynecology Partnering 2010 to 2022, available deals and contracts are listed by: